Cyclerion Therapeutics, Inc. Common Stock (CYCN) Stock Price

CYCNStock

$34.32−87.15%52W

Market Cap$22.95M

P/E—

PEG Ratio—

Div yield—

Beta1.83

CYCN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.32%

Price vs S&P 500 (4W)35.69%

VGM Score28.14

Book Value / Share (Quarterly)$1.20

P/TBV (Annual)0.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)8.36%

Cash Flow / Share (Quarterly)$-1.06

Price vs S&P 500 (YTD)267.32%

Net Profit Margin (TTM)-170.11%

EPS (TTM)$-1.68

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-1.68

Revenue Growth (5Y)-2.05%

EPS (Annual)$-1.11

ROI (Annual)-38.83%

Net Profit Margin (5Y Avg)-1544.15%

Cash / Share (Quarterly)$0.33

Revenue Growth QoQ (YoY)-43.24%

ROA (Last FY)-35.33%

Revenue Growth TTM (YoY)-12.60%

EBITD / Share (TTM)$-1.76

ROE (5Y Avg)-129.39%

Operating Margin (TTM)-176.28%

Cash Flow / Share (Annual)$-0.87

P/B Ratio304.39x

P/B Ratio (Quarterly)2.89x

Net Income / Employee (Annual)$-3,528,000

EV / Revenue (TTM)745.91x

Net Interest Coverage (TTM)-2581.50x

ROA (TTM)-74.87%

EPS Incl Extra (Annual)$-1.11

Current Ratio (Annual)5.15x

Quick Ratio (Quarterly)0.76x

3-Month Avg Trading Volume0.02M

52-Week Price Return-87.15%

Revenue / Employee (TTM)$1,900,000

Tangible BV / Share (Quarterly)$5.26

P/S Ratio (Annual)746.58x

Asset Turnover (Annual)0.21x

52-Week High$59.36

Operating Margin (5Y Avg)-1581.10%

EPS Excl Extra (Annual)$-1.11

26-Week Price Return-21.84%

Quick Ratio (Annual)4.72x

13-Week Price Return38.36%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.82x

Enterprise Value$1.55B

Revenue / Share Growth (5Y)-15.50%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-41.60%

Revenue / Employee (Annual)$2,074,000

Pretax Margin (Annual)-170.11%

Cash / Share (Annual)$0.85

3-Month Return Std Dev106.93%

Net Income / Employee (TTM)$-6,707,000

ROE (Last FY)-38.83%

EPS Basic Excl Extra (Annual)$-1.11

Receivables Turnover (TTM)7.24x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.68

Receivables Turnover (Annual)2.67x

ROI (TTM)-87.96%

P/S Ratio (TTM)746.58x

Pretax Margin (5Y Avg)-1544.15%

Revenue / Share (Annual)$0.65

Tangible BV / Share (Annual)$4.80

Price vs S&P 500 (52W)-88.65%

Year-to-Date Return278.52%

5-Day Price Return-0.80%

EPS Normalized (Annual)$-1.11

ROA (5Y Avg)-87.45%

Net Profit Margin (Annual)-170.11%

Month-to-Date Return-3.80%

Cash Flow / Share (TTM)$-7.92

EBITD / Share (Annual)$-1.15

Operating Margin (Annual)-176.28%

ROI (5Y Avg)-129.39%

EPS Basic Excl Extra (TTM)$-1.68

P/TBV (Quarterly)0.39x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-170.11%

Book Value / Share (Annual)$2.38

Price vs S&P 500 (13W)35.56%

Beta1.83x

Revenue / Share (TTM)$0.45

ROE (TTM)-87.96%

52-Week Low$7.19

vGradeF

gGradeD

mGradeC

vgmGradeD

CYCN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Mar 31, 2026	-$2.66	-$1.33	+50.00%(+$1.33)
Q3 2025	Nov 12, 2025	—	-$2.10	—

CYCN Analyst Recommendations

Feb 2023

Mar 2023

Apr 2023

May 2023

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CYCNCyclerion Therapeutics, Inc. Common Stock	F	D	C	746.6x	-12.6%	—	—	$34.32
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Cyclerion Therapeutics, Inc. Common Stock

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases using soluble guanylate cyclase (sGC) stimulator technology. The company's pipeline includes Olinciguat, Praliciguat, and other candidates targeting rare disease indications. Cyclerion is focused on advancing next-generation sGC stimulators to address unmet medical needs in patients with limited treatment options.